Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2391-2399

  Laheru, Daniel ^a   Shah, Preeti ^a   Rajeshkumar, N V ^a   McAllister, Florencia ^a   Taylor, Gretchen ^a   Goldsweig, Howard ^b   Le, Dung T ^a   Donehower, Ross ^a   Jimeno, Antonio ^a,c   Linden, Sheila ^a   Zhao, Ming ^a   Song, Dongweon ^a,d   Rudek, Michelle A ^a   Hidalgo, Manuel ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Biovex   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Gemcitabine; Pancreatic cancer; Phase I; RAS; Salirasib

Indexed keywords

GEMCITABINE; KRAS PROTEIN; RAS PROTEIN; SALIRASIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FARNESOL; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SALICYLATES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875534210     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9818-6     Document Type: Article

References (22)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
3. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605-1617
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806
6. Guerra C, Schuhmacher AJ, Canamero M, Schuhmacher AJ, Hernández-Porras I, Cañamero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291-302
7. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438
8. Rowinsky EK, Windle JJ, Von Hoff DD (1999) Ras protein farne-syltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652
9. Weisz B, Giehl K, Gana-Weisz M, Ben-Baruch G, Marciano D, Gierschik P et al (1999) A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18:2579-2588
10. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y (2008) Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 61:89-96
11. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y (2002) The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8:555-565
12. Tsimberidou A, Rudek MA, Hong D, Ng CS, Blair J, Goldsweih H et al (2010) Phase I first-i-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol 65(2):235-241
13. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C et al (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652-4661
14. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T et al (2011) MK-1775, a potent Wee1 inhibitor, syner-gizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17:2799-2806
15. Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S et al (2009) Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 15:4138-4146
16. Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, López-Ríos F, Fujiwara K, Matsui WH et al (2010) A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 9:2582-2592
17. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A et al (2008) Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapa-mycin in adult patients with solid tumors. J Clin Oncol 26:4172-4179
18. Zhao M, He P, Xu L, Hidalgo M, Laheru D, Rudek MA (2008) Determination of salirasib (S-trans, trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 869:142-145
19. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New York, pp 409-417
20. Vigil D, Cherfils J, Rossman KL, Der CJ (2010) Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10:842-857
21. Von Hoff DD, Ramanathan RK, Borad M, Laheru D, Smith LS, Wood TE, et al (2011) Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. Oct 3. [Epub ahead of print]
22. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC et al (2010) Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 103:649-655